Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke

Stroke. 2006 Aug;37(8):2168-9. doi: 10.1161/01.STR.0000230286.95513.c2. Epub 2006 Jun 22.

Abstract

Background and purpose: Historically, the use of tissue plasminogen activator (tPA) thrombolysis in pregnancy has been regarded as relatively contraindicated. Underlying this stance has been the concern over the risk of bleeding complications in both mother and child.

Summary of case: We report the successful use of intravenous recombinant tPA (rtPA) thrombolysis in a pregnant woman with acute cardioembolic stroke.

Conclusions: The patient improved clinically, did not develop complications after receiving rtPA, and at 37 weeks' gestation, delivered a healthy infant, demonstrating that rtPA thrombolysis may be used safely in pregnant women.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cesarean Section
  • Embolism / complications*
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Humans
  • Infant, Newborn
  • Injections, Intravenous
  • Live Birth
  • Male
  • Pregnancy
  • Pregnancy Complications, Cardiovascular / drug therapy*
  • Pregnancy Trimester, Second
  • Recombinant Proteins / administration & dosage
  • Stroke / drug therapy*
  • Stroke / etiology*
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator